An investigational factor XI inhibitor shows early promise for treating atrial fibrillation in patients with a degree of kidney impairment.

An updated report on statistics regarding heart failure epidemiology and outcomes has been published by the HFSA.

The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the European Association for the Study of Diabetes.

Topline data were announced from a phase 3 trial evaluating evolocumab in adults at high cardiovascular risk without prior heart attack or stroke.

Results of a systematic review showed that cognitive impairment and neuropsychiatric manifestations are common among patients with various forms of vasculitis.

The South Carolina Medical Affairs Committee conducted a Senate hearing on Wednesday, October 1, 2025, to deliberate S.323, a proposed bill prohibiting abortion in most circumstances, with few ...

Prevention strategies for cardiovascular manifestations of acute and long COVID are discussed in a report published online.

There is lower risk for mortality in patients with cardio-renal-metabolic multimorbidity who maintain hematologic parameters within optimal ranges.

Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study.

A student-led program in which medical students share their own personal stories with illness during a preclinical curriculum enhances learning.

For adults with obesity who do not have diabetes, the oral glucagon-like peptide-1 receptor agonist orforglipron yields significantly greater reductions in body weight than placebo.

Guidelines regarding the management of cardiovascular disease in pregnant patients have been published by the European Society of Cardiology.